Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Janssen Emphasizes Average Net Price Decline As Transparency Momentum Builds In States

Executive Summary

Rebates, discounts drove Janssen's average net price down 4.6% in 2017 even as average list price increased 8.1%; transparency report emphasizes value-based contracts for prostate cancer, diabetes drugs.

Related Content

PhRMA Sues To Block 'Unprecedented' California Price Reporting Law
Pfizer Skeptical About Value-Based Contracting In Current Environment
Pfizer v. J&J Sets Stage For Biosimilar Showdown Over Exclusive Contracts
Sanofi's Drug Pricing Pledge Ties Increases To National Health Expenditure
Rebates, Pricing Pressure Weigh On J&J's Q1 Pharma Sales
Janssen's Drug Pricing Report Emphasizes Value Of Rebates


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts